What is Noble Financial's Forecast for Ocugen Q3 Earnings?

Key Points

• Noble Financial lowered its Ocugen Q3 2026 EPS forecast to a loss of $0.06 from a prior loss estimate of $0.05. It also projects losses of $0.07 per share in Q4 2026 and $0.26 for full-year 2026.
• Ocugen reported a Q2 loss of $0.07 per share, missing the consensus estimate of a $0.05 loss, despite revenue of $1.49 million exceeding the $0.89 million forecast.
• Analyst sentiment remains mixed: Ocugen has a “Moderate Buy” consensus rating and a $9.50 price target, while several firms have recently downgraded earnings expectations or ratings.

Ocugen, Inc. (NASDAQ:OCGN - Free Report) - Analysts at Noble Financial lowered their Q3 2026 earnings estimates for Ocugen in a note issued to investors on Friday, August 7th. Noble Financial analyst R. Leboyer now forecasts that the company will earn ($0.06) per share for the quarter, down from their prior forecast of ($0.05). The consensus estimate for Ocugen's current full-year earnings is ($0.22) per share. Noble Financial also issued estimates for Ocugen's Q4 2026 earnings at ($0.07) EPS and FY2026 earnings at ($0.26) EPS.

A number of other research firms have also weighed in on OCGN. Weiss Ratings lowered Ocugen from a "sell (d-)" rating to a "sell (e+)" rating in a report on Tuesday, June 23rd. Wall Street Zen lowered Ocugen from a "hold" rating to a "sell" rating in a research report on Saturday. Finally, Canaccord Genuity Group decreased their price objective on Ocugen from $12.00 to $11.00 and set a "buy" rating for the company in a research note on Wednesday, May 27th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Ocugen presently has a consensus rating of "Moderate Buy" and a consensus price target of $9.50.

Ocugen Price Performance

Shares of OCGN opened at $1.31 on Tuesday. The stock has a market capitalization of $444.23 million, a PE ratio of -5.04 and a beta of 2.21. The company has a 50 day moving average price of $1.34 and a 200-day moving average price of $1.56. The company has a debt-to-equity ratio of 4.17, a quick ratio of 0.80 and a current ratio of 0.80. Ocugen has a fifty-two week low of $0.96 and a fifty-two week high of $2.73.

Ocugen (NASDAQ:OCGN - Get Free Report) last posted its earnings results on Thursday, August 6th. The company reported ($0.07) EPS for the quarter, missing analysts' consensus estimates of ($0.05) by ($0.02). The business had revenue of $1.49 million for the quarter, compared to analyst estimates of $0.89 million.

Institutional Investors Weigh In On Ocugen

A number of large investors have recently made changes to their positions in OCGN. Diversify Advisory Services LLC purchased a new position in Ocugen in the 2nd quarter worth $25,000. SmartHarvest Portfolios LLC purchased a new stake in Ocugen during the 4th quarter valued at about $31,000. CTC Alternative Strategies Ltd. purchased a new stake in Ocugen during the 1st quarter valued at about $34,000. BNP Paribas Financial Markets increased its holdings in shares of Ocugen by 56.7% in the second quarter. BNP Paribas Financial Markets now owns 36,822 shares of the company's stock valued at $36,000 after purchasing an additional 13,326 shares during the period. Finally, NewEdge Advisors LLC increased its holdings in shares of Ocugen by 198.0% in the second quarter. NewEdge Advisors LLC now owns 36,814 shares of the company's stock valued at $36,000 after purchasing an additional 24,460 shares during the period. 10.27% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In related news, CFO Treerita Essali Johnson-Greene acquired 21,000 shares of the firm's stock in a transaction that occurred on Monday, June 15th. The stock was purchased at an average cost of $1.23 per share, with a total value of $25,830.00. Following the transaction, the chief financial officer directly owned 521,000 shares of the company's stock, valued at $640,830. This trade represents a 4.20% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. 3.95% of the stock is currently owned by company insiders.

Ocugen News Roundup

Here are the key news stories impacting Ocugen this week:

• Negative Sentiment: HC Wainwright cut its estimates across several periods. The firm lowered its FY2026 EPS forecast to a loss of $0.28 from $0.25, FY2027 to a loss of $0.36 from $0.26, and FY2028 to a loss of $0.41 from a prior estimate of $0.05. Quarterly estimates for Q3 2026 through Q4 2027 were also reduced, pointing to a longer period of expected operating losses. Ocugen analyst estimate report
• Negative Sentiment: Long-term earnings expectations were sharply downgraded. HC Wainwright reduced its FY2029 EPS forecast to $0.14 from $0.61 and FY2030 to $1.08 from $1.56. Although the estimates still imply a potential return to profitability, the much lower projections weaken the longer-term earnings outlook.
• Negative Sentiment: Noble Financial also lowered its forecasts. Noble cut its FY2026 EPS estimate to a loss of $0.26 from $0.22 and reduced Q3 2026 EPS to a loss of $0.06 from $0.05 and Q4 2026 to a loss of $0.07 from $0.06. These revisions reinforce concerns about near-term cash consumption and execution.
• Neutral Sentiment: The broader earnings picture remains speculative. Ocugen is expected to remain unprofitable in the near term, while the available estimates project profitability beginning in FY2029. With OCGN trading near its 50-day average and well below its one-year high, investor focus is likely to remain on clinical progress, funding needs and the company’s ability to convert its pipeline into revenue.

About Ocugen

Ocugen Inc is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing gene therapies to treat rare inherited retinal diseases, as well as vaccines designed to address unmet needs in infectious diseases. Headquartered in Malvern, Pennsylvania, the company applies its proprietary gene therapy platform to create novel treatments aimed at preserving and restoring vision, while leveraging strategic partnerships to broaden its vaccine pipeline.

In its gene therapy portfolio, Ocugen is advancing multiple programs targeting retinal disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source